| 产品描述: | GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction. |
| 体内研究: |
GZ-793A (30, 60, 120 or 240 mg/kg; p.o.; once) decreases the number of METH infusions self-administered across each time interval evaluats in a dose-dependent manner. GZ-793A (1-100 µM; 90 min) inhibits METH (5 µM)-evoked fractional dopamine releases. |
| 保存条件: |
2-8°C, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.155 ml |
10.775 ml |
21.55 ml |
| 5 mM |
0.431 ml |
2.155 ml |
4.31 ml |
| 10 mM |
0.215 ml |
1.077 ml |
2.155 ml |
| 50 mM |
0.043 ml |
0.215 ml |
0.431 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |